Skip Navigation


Cardiovascular Research Advance Access first published online on July 11, 2009
This version [Corrected Proof] published online on September 25, 2009

Cardiovascular Research, doi:10.1093/cvr/cvp240
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
84/3/378    most recent
cvp240v4
cvp240v3
cvp240v2
cvp240v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Han, K. H.
Right arrow Articles by Kim, J. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, K. H.
Right arrow Articles by Kim, J. J.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages

Ki Hoon Han1,*,{dagger}, Sunny Lim1,{dagger}, Jewon Ryu1, Cheol-Whan Lee1, Yuna Kim1, Ju-Hee Kang1, Soon-Suk Kang2, Yeong Ki Ahn1, Chan-Sik Park2 and Jae Joong Kim1

1 Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388-1 Pungnap-2-dong Songpa-gu, 138-736 Seoul, Republic of Korea
2 Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

* Corresponding author. Tel: +82 2 3010 3150; fax: +82 2 486 5918. E-mail address: steadyhan{at}amc.seoul.kr

Aims: We investigated the mechanism by which cannabinoid receptors-1 (CB1) and -2 (CB2) modulate inflammatory activities of macrophages.

Methods and results: Real-time polymerase chain reaction showed the predominant CB2 expression in freshly isolated human monocytes. PMA, a potent inducer of differentiation, upregulated CB1 and increased CB1:CB2 transcript ratio from 1:17.5 to 1:3 in 5 days of culture. Immunohistochemistry showed that CB1 protein was colocalized in CD68- and CD36-positive macrophages in human atheroma. Through selective expression of CB1 or CB2 to thioglycollate-elicited peritoneal macrophages, we proved that CB1 and CB2 mediate opposing influences on the production of reactive oxygen species (ROS). Flow cytometry showed that cannabinoid-induced ROS production by macrophages was CB1-dependent. Immunoblotting assays confirmed that macrophage CB1, not CB2, induced phosphorylation of p38-mitogen-activated protein kinase, which modulated ROS production and the subsequent synthesis of tumour necrosis factor-{alpha} and monocyte chemoattractant protein-1. Pull-down assays showed that the Ras family small G protein, Rap1 was activated by CB2. Dominant-negative Rap1 profoundly enhanced CB1-dependent ROS production by macrophages, suggesting CB2 Rap1-dependently inhibits CB1-stimulated ROS production.

Conclusion: CB1 promotes pro-inflammatory responses of macrophages through ROS production, which is negatively regulated by CB2 through Rap1 activation. Blocking CB1 together with selective activation of CB2 may suppress pro-inflammatory responses of macrophages.

KEYWORDS CB1 receptor; CB2 receptor; Macrophages; Reactive oxygen species (ROS); Cytokines; Rap1


Time for primary review: 23 days

The original version was incorrect. Author details of reference 11 have been corrected.

{dagger} K.H.H. and S.L. contributed equally to the work as first authors.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article

Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
Stephan Immenschuh
Cardiovasc Res 2009 84: 341-342. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Cardiovasc ResHome page
S. Immenschuh
Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
Cardiovasc Res, December 1, 2009; 84(3): 341 - 342.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.